Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of funding her Department provides to help tackle (a) less survivable cancers compared to (b) other cancers; and if she will make it her policy to (i) create a framework assessing the challenges around cancers with lower survival rates and (ii) increase funding for those cancers.

The Government is taking steps through NHS England to improve outcomes for cancer patients, including those with less survivable cancers. Making improvements across different cancer types is critical to helping achieve the NHS Long Term Plan ambition of diagnosing 75% of patients at an early stage by 2028 and reducing inequalities in cancer survival. NHS England has commissioned new cancer clinical audits covering five cancer types, some of which are less survivable: pancreatic cancer, ovarian cancer, non-Hodgkin lymphoma, kidney cancer and primary and metastatic breast cancer. All five audits will cover care delivered in England and Wales and will see an investment of approximately £5.4 million for an initial period of three years.

NHS England is responsible for funding allocations to integrated care boards (ICBs). ICBs then decide how that money is spent within the local integrated care system. The allocations process is independent of Government and NHS England takes advice on the underlying formula from the independent Advisory Committee on Resource Allocation. NHS England produces a target allocation, or 'fair share' for each area, based on a complex assessment of factors such as demography, morbidity, deprivation, and the unavoidable cost of providing services in different areas. This means that funding decisions are fair and equitable.

Delivering more research is key to understanding and assessing the challenges around cancers with lower survival rates. As with other Government funders of health research, the National Institute for Health and Care Research (NIHR) does not allocate funding for specific disease areas, including less survivable cancers. The level of research spend in a particular area is driven by factors including scientific potential and the number and scale of successful funding applications. The NIHR welcomes funding applications for research into any aspect of human health, including less survivable cancers.